Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stevanato Group excels in 2022, eyes high value solutions growth

Stevanato Group's strong financial performance in 2022, driven by high value solutions and operational efficiency, sets a solid foundation for future growth.
Strategic focus on biologics and high growth markets, along with optimized capital spending, positions the company for long-term success.
Challenges in pricing management and capacity ramp-up require careful navigation, while opportunities in expanding high value solutions and market demand offer avenues for growth.
Overall, Stevanato Group's performance reflects resilience, strategic foresight, and a commitment to value creation, signaling a positive trajectory for the company.

Stevanato Group reports strong Q1 results, eyes biologics market growth

Stevanato Group's Q1 performance reflects robust revenue growth, profitability, and a strong order backlog, underpinned by strategic collaborations and market focus.
While facing challenges such as pricing pressures and market dynamics, the company is well-positioned to leverage opportunities in the biologics sector and innovative drug delivery solutions.
With a reiterated full-year revenue guidance and a focus on operational excellence, Stevanato Group demonstrates resilience and strategic foresight in navigating the evolving healthcare landscape.
Investors can find confidence in the company's performance, strategic strengths, and growth opportunities amidst the challenges and uncertainties in the market.

Stevanato Group SpA reports robust Q2 performance and eyes growth

Stevanato Group SpA's Q2 2023 earnings call highlighted strong performance, growth prospects, and strategic initiatives amidst market challenges.
The company's financial results, revenue breakdown, and guidance underscore its resilience and potential for sustained growth.
Addressing challenges like currency fluctuations and market dynamics while seizing growth opportunities will be key for Stevanato Group SpA's future success.

Stevanato Group reports strong Q3 earnings, eyes biologics market growth

Stevanato Group's Q3 2023 performance showcased robust revenue growth and margin expansion, despite challenges in specific segments. The company's strong presence in key biologics markets and strategic priorities for sustainable growth position it well for the future. Opportunities in expanding markets and a solid order backlog provide a positive outlook.

Stevanato Group reports 10% revenue growth in Q4 2023

Stevanato Group's 2023 performance reflects growth driven by high-value solutions and strong demand.
Despite challenges like margin pressure and supply chain issues, the company remains confident in achieving growth.
Opportunities lie in expanding capacity, enhancing product mix, and capitalizing on backlog growth.
The company anticipates a stronger second half of 2024 and foresees material revenue impact from biologic products in 2025.

Stevanato Group faces Q1 challenges, invests in growth opportunities

Stevanato Group's Q1 2024 performance was impacted by industry-wide challenges, but the company remains focused on strategic priorities and operational efficiencies.
Despite revenue decline and margin impacts, the company's commitment to growth through expansion projects and high-value solutions showcases resilience and forward-thinking.
Challenges in vial demand and customer delays are being addressed through cost management and strategic actions, while opportunities in new investments and operational focus are being pursued.
The company's leadership position, solid strategy, and emphasis on execution position Stevanato Group for long-term success despite near-term headwinds.

Stevanato Group reports modest revenue growth amidst margin challenges

Stevanato Group delivered mixed results in Q2, with revenue growth driven by the Biopharmaceutical and Diagnostic Solutions segment.
While facing margin pressures and operational challenges, the company's focus on high-value solutions and efficiency improvements bodes well for long-term prospects.
Navigating through current obstacles, Stevanato Group remains optimistic about its ability to drive growth and enhance profitability.

Stevanato Group adjusts guidance amidst challenges, eyes growth opportunities

Stevanato Group's Q3 2024 performance was impacted by challenges in Engineering and the U.S., leading to a revised full-year guidance.
Despite operational challenges, the company demonstrated strengths in capacity expansion, innovation, and revenue growth.
Addressing challenges in vial destocking and segment optimization presents opportunities for future growth and profitability.
Analyst questions highlighted the need to navigate current challenges while capitalizing on opportunities for strategic advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A.

Stevanato Group and Gerresheimer AG Present EZ-fill Smart™, a New and Innovative Ready-To-Use Vial Platform

Stevanato Group and DWK Life Sciences Sign Non-Exclusive Distribution Agreement for EZ-fill® Platform Products

Stevanato Group to Report Third Quarter 2022 Financial Results on November 8, 2022

SANTA BARBARA, Calif. , Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group  (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Assertio Therapeutics Inc

ASRT vs. STVN: Which Stock Is the Better Value Option?

ASRT vs. STVN: Which Stock Should Value Investors Buy Now?

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Gr

Stevanato Group and Gerresheimer AG Announce Collaboration on the Development of an Innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Stevanato Group S.p.A. (NYSE:STVN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Lisa Miles - Investor Relations Franco Stevanato - Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Justin Lin - William Blair Derik De Bruin - Bank of America Patrick Donnelly - Citi Steven Couche - Jefferies John Sourbeer - UBS Operator Good afternoon.

Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q2 2022 Results - Earnings Call Transcript

Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2022. Second Quarter 2022 Highlights (compared to the same period last year) Second quarter revenue increased 15% to €234.2 million, Diluted earnings per share of €0.12 and adjusted diluted earnings per s

Stevanato Group Reports Second Quarter 2022 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. (EST). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EST) on Thursday, August 4, 2022 to disc

Stevanato Group to Report Second Quarter 2022 Financial Results on August 4, 2022

Jazz Pharmaceuticals

JAZZ vs. STVN: Which Stock Is the Better Value Option?

JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) announces the publication of its Sustainability Report 2021.

Stevanato Group Releases Sustainability Report 2021, Highlighting the Environmental, Social and Governance (ESG) Performance of the Group

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that all resolutions proposed to Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on June 1, 2022 were passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepar

Stevanato Group Announces Voting Results from its Annual General Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced the acquisition of a new industrial complex in Cisterna di Latina, Italy. The new facility is expected to strengthen Stevanato Group's presence in Europe and expand the Company's production capabilities to satisfy increased demand for its standard and p

Stevanato Group Adding New Capacity in Italy Amid Growing Demand for Its Market-Leading Solutions

Stevanato Group S.p.A. (NYSE:STVN ) Q1 2022 Results Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Miles - Head of Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer and Chief Operating Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America John Kreger - William Blair Dave Windley - Jefferies Paul Knight - KeyBanc Tim Daley - Wells Fargo John Sourbeer - UBS Drew Ranieri - Morgan Stanley Lisa Miles Good morning, and thank you for joining us.

Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q1 2022 Results - Earnings Call Transcript

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2022. First Quarter 2022 Highlights (compared to the same period last year) First quarter revenue increased 10% to €212.1 million, diluted earnings per share were €0.10 and adjusted diluted earnings per sh

Stevanato Group Reports First Quarter 2022 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it has published the agenda for the 2022 Annual General Meeting of Shareholders (“AGM”), which will be held virtually on June 1, 2022, beginning at 4:00 p.m. (CEST) / 10:00 a.m. (EDT). Stevanato Group's AGM notice, explanatory notes, other AGM materials, and instructions for v

Stevanato Group Publishes Materials for 2022 Annual General Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector. The agreement makes Stevanato Group an exclusive manufacturing partner for the device, offering a full set of capabilities to its pharmace

Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector

PIOMBINO DESE, Italy & SANTA BARBARA, Calif.--(BUSINESS WIRE)--Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their collaboration. This agreement between the compani

Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the first quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14

Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced the filing of Amendment No. 1 (the “Form 20-F/A”) to its 2021 Annual Report on Form 20-F (the “Form 20-F”), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 8, 2022, to submit the Interactive Data File and to provide cert

Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN) (the “Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the acquisition of a facility in Zhangjiagang for a new plant where the Company expects to begin renovations in the spring 2022, as part of the latest phase of its expansion in China. The new facility is located near the Company's drug containment solut

Stevanato Group to Create Manufacturing Hub in China

Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q4 2021 Results - Earnings Call Transcript

News for Stevanato Group SpA Stock (STVN)